Publications by authors named "Raphael Pelloquin"
Article Synopsis
- A significant increase in food consumption outside the home is noted, impacting individual diets and health negatively, with limited data on this trend due to a lack of dietary surveys in certain regions.
- The study aimed to create and test two survey modules (one long and one short) in Burkina Faso and Vietnam to measure food consumed away from home in relation to regular Household Consumption and Expenditure Surveys.
- Although the modules showed good agreement with 24-hour dietary recalls (over 77% accuracy), they underestimated energy intake and overestimated spending on food consumed outside the home, indicating a need for better tools to assess these dietary habits globally.
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Open Forum Infect Dis
December 2023
Article Synopsis
- The NAMSAL-ANRS-12313 trial compared the efficacy of dolutegravir (DTG) versus efavirenz (EFV400) in treating HIV in low-income countries over a 96-week period, demonstrating DTG's noninferiority and continued effectiveness at 192 weeks.
- At week 192, viral suppression remained higher in participants on the DTG regimen (69%) compared to those on EFV400 (62%), with slight differences in new viral failures and serious adverse events noted between the two groups.
- Both treatment groups experienced significant weight gain, with participants on DTG/TDF/3TC gaining an average of 9.4 kg and an increase in obesity prevalence, raising concerns about
Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study.
Lancet Infect Dis
March 2024
Background: The use of specific anti-Ebola virus therapy, especially monoclonal antibodies, has improved survival in patients with Ebola virus disease. We aimed to assess the effect of monoclonal antibodies on anti-Ebola virus antibody responses in survivors of the 2018-20 Ebola outbreak in the Democratic Republic of the Congo.
Methods: In this observational prospective cohort study, participants were enrolled at three Ebola survivor clinics in Beni, Mangina, and Butembo (Democratic Republic of the Congo).
Interest of seroprevalence surveys for the epidemiological surveillance of the SARS-CoV-2 pandemic in African populations: Insights from the ARIACOV project in Benin.
Trop Med Int Health
July 2023
Background: Many SARS-CoV-2 seroprevalence surveys since the end of 2020 have disqualified the first misconception that Africa had been spared by the pandemic. Through the analysis of three SARS-CoV-2 seroprevalence surveys carried out in Benin as part of the ARIACOV project, we argue that the integration of epidemiological serosurveillance of the SARS-CoV-2 infection in the national surveillance packages would be of great use to refine the understanding of the COVID-19 pandemic in Africa.
Methods: We carried out three repeated cross-sectional surveys in Benin: two in Cotonou, the economic capital in March and May 2021, and one in Natitingou, a semi-rural city in the north of the country in August 2021.
High and Rapid Increase in Seroprevalence for SARS-CoV-2 in Conakry, Guinea: Results From 3 Successive Cross-Sectional Surveys (ANRS COV16-ARIACOV).
Open Forum Infect Dis
May 2022
Article Synopsis
- Three seroprevalence surveys were conducted in Conakry, Guinea, over a period of 6 months to assess COVID-19 spread using cluster sampling.* -
- Seroprevalence rates rose significantly from 17.3% in December 2020 to 42.4% by June 2021, indicating persistent transmission across all age groups.* -
- These findings could help shape effective public health response strategies to manage the epidemic in the community.*
We conducted 2 independent population-based SARS-CoV-2 serosurveys in Yaoundé, Cameroon, during January 27-February 6 and April 24-May 19, 2021. Overall age-standardized SARS-CoV-2 IgG seroprevalence increased from 18.6% in the first survey to 51.
View Article and Find Full Text PDFHigh Prevalence of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (Anti-SARS-CoV-2) Antibodies After the First Wave of Coronavirus Disease 2019 (COVID-19) in Kinshasa, Democratic Republic of the Congo: Results of a Cross-sectional Household-Based Survey.
Clin Infect Dis
March 2022
Article Synopsis
- In October 2020, a study in Kinshasa, Democratic Republic of the Congo, aimed to determine the true prevalence of SARS-CoV-2 antibodies in the general population, revealing a much higher level of infection than the officially reported cases.
- The serosurvey involved 1233 participants and found a weighted, age-standardized seroprevalence of 16.6%, with the majority being women and a mean age of 32.4 years.
- The study highlighted an infection-to-case ratio of 292:1, emphasizing the need for ongoing serosurveys to inform public health policies regarding COVID-19 response measures.